ATH 0.00% 0.5¢ alterity therapeutics limited

Ann: Alterity Presents New Data on Multiple System Atrophy, page-4

  1. 2,760 Posts.
    lightbulb Created with Sketch. 963
    I agree, rising. The "positive" issue is that they seem to take measurements at least every 3 months. So in the open, biometric study, we may get early results as soon as some 7-8 patients have taken ATH434 for 3 -6 months (??). This is only if the company is willing to tell these results, i.e. if the results are positive. But IMO they have the early results pretty soon. Looks like they will recruit 2 patients per month so they have now perhaps 7 patients taking ATH434, the first ones already for 3 months.

    The main interim outcome measures will be UMSARS, NNIPPS, NFL, and alpha-synuclein during the study, and perhaps MRI only after 12 months. These new measures in the presented poster are too new at this time.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.000(0.00%)
Mkt cap ! $26.22M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 400000 0.6¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 1398400 2
View Market Depth
Last trade - 09.31am 16/05/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.